Assessments of Two Rat Models of Fulminant Hepatic Failure for Testing Artificial Liver Devices

  • E. Chirito
  • B. Reiter
  • C. Lister
  • T. M. S. Chang


Research in the treatment of fulminant hepatic failure is hampered by the lack of a suitable experimental animal model. We have looked into two animal models which can be conveniently used in large numbers for statistical analysis of effects of hemoperfusion on survival. One is carbon tetrachloride induced fulminant hepatic failure (1); another is the galactosamine induced fulminant hepatic failure rat model (2,3,4). These models seem to fulfill many of the requirements such as severe fulminant hepatic failure, reversibility and safety for research personnel. However, these animal models have not yet been used for the assessment of the effectiveness of treatment regimes for fulminant hepatic failure. Hemoperfusion has been used for patients with hepatic coma (5–13). The original finding (5,6) of hemoperfusion resulting in improvements of consciousness in grade 4 hepatic coma patients have now been supported by all centers. However, the effects on hemoperfusion in the improvements of long-term survival is not yet conclusive. For this, studies of a large series including rigid control studies is required. This is not too feasible in acute fulminant hepatic failure because of relatively small numbers of patients and the variations due to etiology, age, grade of coma and other factors.


Carbon Tetrachloride Blood Flow Rate Fulminant Hepatic Failure Cellulose Nitrate Heparin Dosage 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Paquet, K.J. and Kamphansen, V. (1975) Acta Hepato-Gastro-buterol, 22, 84–88.Google Scholar
  2. 2.
    Keppler, D., Lesch, R., Reuter, W., Decker, K. (1968) Pathology, 9, 279–290.Google Scholar
  3. 3.
    Decker, K., Keppler, D. (1974) Rev. Physiol. Biochem. Pharmacol., 71, 77–106.Google Scholar
  4. 4.
    Decker, K., Keppler, D. (1974) Progress in Liver Diseases, 4, 183–199.Google Scholar
  5. 5.
    Chang, T.M.S. (1972) Lancet, 2, 1371–1372.PubMedCrossRefGoogle Scholar
  6. 6.
    Chang, T.M.S., Migchelsen, M. (1973) Trans. Amer. Soc. Artif. Intern. Organs, 19, 314–319.Google Scholar
  7. 7.
    Gazzard, B.G., Weston, M.J., Murray-Lyon, I.M., Flax, H., Record, C.O., Portman, B., Langley, P.G., Dunlop, E.H., Mellon, P.J., Ward, M.D., Williams, R. (1974) Lancet, 1(7870), 1301–1305.PubMedCrossRefGoogle Scholar
  8. 8.
    Chang, T.M.S. (1976) Kidney Int., 10, S305-S311.Google Scholar
  9. 9.
    Gelfand, M. In this volume.Google Scholar
  10. 10.
    Amano, I., Kano, H., Takahira, H., Yamamoto, Y., Itoh, K., Iwatsuki, S., Maeda, K. and Ohta, K. In this volume.Google Scholar
  11. 11.
    Odaka, M. In this volume.Google Scholar
  12. 12.
    Silk, D.B.A. and William, R. In this volume.Google Scholar
  13. 13.
    Chang, T.M.S. (1969) Can. J. Physiol. Pharmacol., 47, 1043–1045.Google Scholar
  14. 14.
    Chang, T.M.S. (1972) Artificial Cells. Charles C. Thomas, Publisher, Springfield, Illinois, U.S.A.Google Scholar
  15. 15.
    Chang, T.M.S. (1976) Kidney Int., 10, S218-S224.Google Scholar
  16. 16.
    Chirito, E., Reiter, B., Lister, C. and Chang, T.M.S. (1977) Artificial Organs J., 1, 76–83.CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1978

Authors and Affiliations

  • E. Chirito
    • 1
  • B. Reiter
    • 1
  • C. Lister
    • 1
  • T. M. S. Chang
    • 1
  1. 1.Artificial Organs Research Unit, McIntyre Medical Sciences BuildingMcGill UniversityMontrealCanada

Personalised recommendations